{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:21:21Z","timestamp":1791015681024,"version":"4.1.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003508","name":"Universitat de Val\u00e8ncia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003508","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015682","name":"INCLIVA Instituto de Investigaci\u00f3n Sanitaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015682","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","surveyophthalmol.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.survophthal.2024.02.005","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T12:07:33Z","timestamp":1709294853000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis"],"prefix":"10.1016","author":[{"given":"Amparo","family":"Ortiz-Seller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honorio","family":"Barranco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Pascual-Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Morcillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.survophthal.2024.02.005_bib1","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/bjophthalmol-2017-311662","article-title":"Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity","volume":"103","author":"Bai","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib3","doi-asserted-by":"crossref","first-page":"022","DOI":"10.1055\/s-0040-1713181","article-title":"Update in the Treatment of Retinopathy of Prematurity","volume":"39","author":"Bancalari","year":"2022","journal-title":"Am J Perinatol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.02.005_bib4","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/11206721211073405","article-title":"New trends in intravitreal anti-VEGF therapy for ROP","volume":"32","author":"Beccasio","year":"2022","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4103\/tjo.tjo_69_18","article-title":"Bevacizumab or laser for aggressive posterior retinopathy of prematurity","volume":"8","author":"Blair","year":"2018","journal-title":"Taiwan J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/srep27082","article-title":"Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy","volume":"6","author":"Chan","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.survophthal.2024.02.005_bib7","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-022-02489-6","article-title":"Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2024.02.005_bib10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/bjophthalmol-2019-314610","article-title":"Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation","volume":"104","author":"Chen","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.02.005_bib11","first-page":"4565216","article-title":"Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age","volume":"2018","author":"Chen","year":"2018"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28987-6","article-title":"A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity","volume":"8","author":"Cheng","year":"2018","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.survophthal.2024.02.005_bib13","doi-asserted-by":"crossref","first-page":"e1004","DOI":"10.1111\/aos.14460","article-title":"Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity","volume":"98","author":"Cheng","year":"2020","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-021-02166-3","article-title":"ROB-MEN: a tool to assess risk of bias due to missing evidence in network meta-analysis","volume":"19","author":"Chiocchia","year":"2021","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib15","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1038\/s41598-021-83985-5","article-title":"Management of retinopathy of prematurity (ROP) in a Polish cohort of infants","volume":"11","author":"Chmielarz-Czarnoci\u0144ska","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.survophthal.2024.02.005_bib17","first-page":"290","article-title":"Evaluation of Treatment Models in the Treatment of Retinopathy of Prematurity. The Medical Bulletin of Sisli Etfal","volume":"53","author":"Demir","year":"2019","journal-title":"Hospital"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib18","first-page":"545","article-title":"Evaluation of the Effect of Different Treatment Management on Refractive Outcomes in Severe Retinopathy of Prematurity. The Medical Bulletin of Sisli Etfal","volume":"55","author":"Demir","year":"2021","journal-title":"Hospital"},{"key":"10.1016\/j.survophthal.2024.02.005_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/9781118951651.ch3","article-title":"Model Fit, Model Comparison and Outlier Detection","author":"Dias","year":"2018","journal-title":"Netw Meta\u2010Analysis Decis Mak"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5935\/0004-2749.20180005","article-title":"Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?","volume":"81","author":"Dikci","year":"2018","journal-title":"Arq Bras Oftalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3928\/01913913-20191104-01","article-title":"Comparison of the efficacy between intravitreal aflibercept and laser photocoagulation in the treatment of retinopathy of prematurity","volume":"57","author":"Ekinci","year":"2020","journal-title":"J Pedia Ophthalmol Strabismus"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib22","doi-asserted-by":"crossref","first-page":"93.e1","DOI":"10.1016\/j.jaapos.2020.11.020","article-title":"Comparison of two different doses of intravitreal aflibercept in the treatment of retinopathy of prematurity","volume":"25","author":"Ekinci","year":"2021","journal-title":"J AAPOS"},{"issue":"6","key":"10.1016\/j.survophthal.2024.02.005_bib23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arq Bras Oftalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/2041-210X.13727","article-title":"Convergence assessment for Bayesian phylogenetic analysis using MCMC simulation","volume":"13","author":"Fabreti","year":"2022","journal-title":"Methods Ecol Evol"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.survophthal.2022.11.007","article-title":"Retinopathy of prematurity: A review of pathophysiology and signaling pathways","volume":"68","author":"Fevereiro-Martins","year":"2023","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2024.02.005_bib26","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","article-title":"Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial","volume":"6","author":"Fleck","year":"2022","journal-title":"Ophthalmol Retin"},{"issue":"10","key":"10.1016\/j.survophthal.2024.02.005_bib27","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ophtha.2022.05.019","article-title":"Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes","volume":"129","author":"Freedman","year":"2022","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.survophthal.2024.02.005_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.survophthal.2024.02.005_bib29","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2024.02.005_bib30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jpeds.2008.07.002","article-title":"Retinopathy of prematurity and the peripheral retina","volume":"153","author":"Good","year":"2008","journal-title":"J Pedia"},{"issue":"5","key":"10.1016\/j.survophthal.2024.02.005_bib31","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5935\/0004-2749.20150079","article-title":"Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity","volume":"78","author":"Gunay","year":"2015","journal-title":"Arq Bras Oftalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.02.005_bib32","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey","volume":"42","author":"Gunay","year":"2017","journal-title":"Curr Eye Res"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/org.4.4.7415","article-title":"Role of VEGF in organogenesis","volume":"4","author":"Haigh","year":"2008","journal-title":"Organogenesis"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/ije\/dyt043","article-title":"Markov Chain Monte Carlo: an introduction for epidemiologists","volume":"42","author":"Hamra","year":"2013","journal-title":"Int J Epidemiol"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib35","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1111\/aos.13004","article-title":"Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison","volume":"96","author":"Han","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2024.02.005_bib36","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","article-title":"Intravitreal bevacizumab for retinopathy of prematurity: refractive error results","volume":"155","author":"Harder","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","article-title":"Pathophysiology and Mechanisms of Severe Retinopathy of Prematurity","volume":"122","author":"Hartnett","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaapos.2013.12.009","article-title":"Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy","volume":"18","author":"Henaine-Berra","year":"2014","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10103-011-1021-z","article-title":"Laser treatment for retinopathy of prematurity","volume":"28","author":"Houston","year":"2013","journal-title":"Lasers Med Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2024.02.005_bib40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2024.02.005_bib41","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"Isaac","year":"2015","journal-title":"J AAPOS"},{"issue":"11","key":"10.1016\/j.survophthal.2024.02.005_bib43","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","article-title":"Factors Associated With Reactivation After Intravitreal Bevacizumab or Ranibizumab Therapy in Infants With Retinopathy of Prematurity","volume":"41","author":"Iwahashi","year":"2021","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.survophthal.2024.02.005_bib44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4103\/0301-4738.71689","article-title":"Technical aspects of laser treatment for acute retinopathy of prematurity under topical anesthesia","volume":"58","author":"Jalali","year":"2010","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013344","article-title":"Anaesthesia modalities during laser photocoagulation for retinopathy of prematurity: a retrospective, longitudinal study","volume":"7","author":"Jiang","year":"2017","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.survophthal.2024.02.005_bib46","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","article-title":"Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity","volume":"38","author":"Jin","year":"2018","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.survophthal.2024.02.005_bib47","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children","volume":"42","author":"Kabata\u015f","year":"2017","journal-title":"Curr Eye Res"},{"issue":"6","key":"10.1016\/j.survophthal.2024.02.005_bib48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3341\/kjo.2018.0011","article-title":"Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes","volume":"32","author":"Kang","year":"2018","journal-title":"Korean J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2024.02.005_bib49","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/bjophthalmol-2018-312272","article-title":"Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety","volume":"103","author":"Kang","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2024.02.005_bib50","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/aos.13008","article-title":"Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity","volume":"94","author":"Karkhaneh","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000489023","article-title":"Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1","volume":"240","author":"Kimyon","year":"2018","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.survophthal.2024.02.005_bib52","first-page":"13","article-title":"Comparison of Ocular and Developmental Outcomes in Laser-and Bevacizumab-treated Infants with Retinopathy of Prematurity. Ophthalmology","volume":"3","author":"Kong","year":"2015","journal-title":"Res: Int J"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib53","doi-asserted-by":"crossref","first-page":"42384","DOI":"10.1136\/bmjopen-2020-042384","article-title":"Original research: Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis","volume":"11","author":"Kong","year":"2021","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.survophthal.2024.02.005_bib54","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jamaophthalmol.2021.3192","article-title":"Choice of Dose Level for a Randomized Clinical Trial of Low-Dose Bevacizumab vs Laser for Type 1 Retinopathy of Prematurity","volume":"139","author":"Kraker","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000439182","article-title":"Refractive error in patients with retinopathy of prematurity after laser photocoagulation or bevacizumab monotherapy","volume":"234","author":"Kuo","year":"2015","journal-title":"Ophthalmologica"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7180\/kmj.22.145","article-title":"Revascularization of immature retinas with retinopathy of prematurity using combination therapy of deferred laser treatment after a single intravitreal bevacizumab injection","volume":"38","author":"Lee","year":"2023","journal-title":"KMJ"},{"key":"10.1016\/j.survophthal.2024.02.005_bib57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","article-title":"Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment","volume":"192","author":"Lee","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12886-018-0973-1","article-title":"The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units","volume":"18","author":"Leng","year":"2018","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.02.005_bib59","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3928\/23258160-20200228-07","article-title":"Functional and morphologic findings at four years after intravitreal bevacizumab or laser for type 1 ROP","volume":"51","author":"Lepore","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib60","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.survophthal.2024.02.005_bib61","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.survophthal.2024.02.005_bib62","first-page":"4321","article-title":"Long-term Vision and Neurodevelopmental Outcomes in Laser and Bevacizumab-Treated Infants with Retinopathy of Prematurity","volume":"56","author":"Li","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib63","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12886-018-0685-6","article-title":"Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)","volume":"18","author":"Li","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.02.005_bib64","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2147\/OPTH.S110717","article-title":"Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity","volume":"10","author":"Lin","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2024.02.005_bib65","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2024.02.005_bib66","article-title":"Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China","author":"Linghu","year":"2022","journal-title":"Front Med Front Media SA; May 31"},{"key":"10.1016\/j.survophthal.2024.02.005_bib67","first-page":"2311","article-title":"Profile of conbercept in the treatment of\u00a0neovascular age-related macular degeneration","volume":"9","author":"Lu","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"10.1016\/j.survophthal.2024.02.005_bib68","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1007\/s00417-022-05663-0","article-title":"Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection","volume":"260","author":"Lu","year":"2022","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib69","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12886-019-1067-4","article-title":"Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40\u2009weeks post menstrual age: a retrospective case series study","volume":"19","author":"Lyu","year":"2019","journal-title":"BMC Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2024.02.005_bib70","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"9","key":"10.1016\/j.survophthal.2024.02.005_bib71","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1177\/0962280219889080","article-title":"Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis","volume":"29","author":"McGrath","year":"2020","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"5","key":"10.1016\/j.survophthal.2024.02.005_bib73","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jaapos.2006.05.005","article-title":"Long-Term Refractive and Biometric Outcomes Following Diode Laser Therapy for Retinopathy of Prematurity","volume":"10","author":"McLoone","year":"2006","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus {JAAPOS}"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/joco.joco_193_21","article-title":"Comparison of Clinical Outcomes of Intravitreal Bevacizumab and Aflibercept in Type 1 Prethreshold Retinopathy of Prematurity in Posterior Zone II","volume":"34","author":"Milani","year":"2022","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.02.005_bib75","first-page":"135","article-title":"Review of effects of anti-VEGF treatment on refractive error","volume":"8","author":"Mintz-Hittner","year":"2016","journal-title":"Eye Brain"},{"issue":"9","key":"10.1016\/j.survophthal.2024.02.005_bib76","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.survophthal.2024.02.005_bib77","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib78","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40942-022-00364-6","article-title":"Progression of retinal vascularization after intravitreal anti-vascular-endothelial growth factor therapy in retinopathy of prematurity","volume":"8","author":"Mirghorbani","year":"2022","journal-title":"Int J Retin Vitr"},{"issue":"6","key":"10.1016\/j.survophthal.2024.02.005_bib79","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/aos.12339","article-title":"Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity","volume":"92","author":"Moran","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2024.02.005_bib80","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1038\/s41433-020-01321-z","article-title":"Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity","volume":"35","author":"Mori","year":"2021","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib81","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib82","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaapos.2017.12.005","article-title":"Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study","volume":"22","author":"Morrison","year":"2018","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus {JAAPOS}"},{"issue":"3","key":"10.1016\/j.survophthal.2024.02.005_bib83","first-page":"365","article-title":"Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone","volume":"101","author":"Mueller","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2024.02.005_bib84","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00417-021-05137-9","article-title":"Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity","volume":"259","author":"Murakami","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib85","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.survophthal.2024.02.005_bib86","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jclinepi.2023.02.016","article-title":"A multifaceted graphical display, including treatment ranking, was developed to aid interpretation of network meta-analysis","volume":"157","author":"Nevill","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.survophthal.2024.02.005_bib87","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.12659\/MSM.897095","article-title":"Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis","volume":"22","author":"Nicoar\u0103","year":"2016","journal-title":"Med Sci Monit"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib89","first-page":"355","article-title":"Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: A 5 year follow-up","volume":"109","author":"O\u2019Keeffe","year":"2016","journal-title":"Ir Med J"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib90","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/jrsm.1373","article-title":"MetaInsight: An interactive web\u2010based tool for analyzing, interrogating, and visualizing network meta\u2010analyses using R\u2010shiny and netmeta","volume":"10","author":"Owen","year":"2019","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib91","article-title":"CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib92","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ophtha.2022.11.012","article-title":"Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study","volume":"130","author":"Patel","year":"2023","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2024.02.005_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129383","article-title":"A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity","volume":"10","author":"Pertl","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib94","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.survophthal.2020.12.002","article-title":"Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3,701 eyes","volume":"66","author":"Popovic","year":"2021","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.02.005_bib95","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0161-6420(92)31968-2","article-title":"Development of myopia in infants with birth weights less than 1251 grams. The Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"99","author":"Quinn","year":"1992","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib96","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40942-021-00334-4","article-title":"Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity","volume":"7","author":"Riazi-esfahani","year":"2021","journal-title":"Int J Retin Vitr"},{"issue":"9","key":"10.1016\/j.survophthal.2024.02.005_bib97","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","article-title":"Comparison of Intravitreal Bevacizumab and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity","volume":"2","author":"Roohipoor","year":"2018","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib98","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joco.2018.10.008","article-title":"Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity","volume":"31","author":"Roohipoor","year":"2019","journal-title":"J Curr Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib99","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11845-017-1684-y","article-title":"Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity","volume":"187","author":"\u015eahin","year":"2018","journal-title":"Ir J Med Sci (1971 -)"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib100","doi-asserted-by":"crossref","DOI":"10.1111\/j.1755-3768.2012.02552.x","article-title":"What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?","volume":"91","author":"Spandau","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib101","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J R Stat Soc Ser B Stat Method"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib102","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1111\/aos.14852","article-title":"Ranibizumab in retinopathy of prematurity \u2013 one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study","volume":"100","author":"Stahl","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2024.02.005_bib103","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pedia"},{"issue":"10208","key":"10.1016\/j.survophthal.2024.02.005_bib104","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib105","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.survophthal.2024.02.005_bib106","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.survophthal.2024.02.005_bib107","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.survophthal.2024.02.005_bib108","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000449530","article-title":"The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab","volume":"236","author":"Sukgen","year":"2016","journal-title":"Ophthalmologica"},{"issue":"2","key":"10.1016\/j.survophthal.2024.02.005_bib109","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00417-016-3443-6","article-title":"Treatment for stage 4A retinopathy of prematurity: laser and\/or ranibizumab","volume":"255","author":"Sukgen","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2024.02.005_bib110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2024.02.005_bib111","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10792-021-02188-z","article-title":"Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment","volume":"42","author":"S\u00fcren","year":"2022","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.02.005_bib112","article-title":"Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis","volume":"9","author":"Taher","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"10.1016\/j.survophthal.2024.02.005_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225643","article-title":"Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review","volume":"14","author":"Tan","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.survophthal.2024.02.005_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.101018","article-title":"Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)","volume":"88","author":"Tsai","year":"2022","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"10.1016\/j.survophthal.2024.02.005_bib115","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s10792-022-02480-6","article-title":"Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review","volume":"43","author":"Tsiropoulos","year":"2023","journal-title":"Int Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2024.02.005_bib116","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.semperi.2019.05.011","article-title":"Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity","volume":"43","author":"VanderVeen","year":"2019","journal-title":"Semin Perinatol"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib117","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2298\/VSP150831191V","article-title":"Refractive errors in premature infants with retinopathy of prematurity after anti-vascular endothelial growth factor (anti-VEGF) therapy","volume":"74","author":"Vujanovi\u0107","year":"2017","journal-title":"Vojn Pregl"},{"issue":"12","key":"10.1016\/j.survophthal.2024.02.005_bib118","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2024.02.005_bib119","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2024.02.005_bib120","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2024.02.005_bib121","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/bjophthalmol-2020-318026","article-title":"Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial","volume":"106","author":"Wu","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2024.02.005_bib122","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/IAE.0000000000003249","article-title":"Clinical Features and Outcomes of Infants with Retinopathy of Prematurity Who Fail Antivascular Endothelial Growth Factor Therapy","volume":"41","author":"Xu","year":"2021","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.survophthal.2024.02.005_bib123","first-page":"1158","article-title":"Bevacizumab for retinopathy of prematurity: 2-year neurodevelopmental follow-up","volume":"38","author":"Zayek","year":"2020","journal-title":"Am J Perinatol"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib124","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.oret.2021.12.016","article-title":"Effect of low-dose intravitreal bevacizumab and ranibizumab on regression and late reactivation in retinopathy of prematurity in the treatment-na\u00efve eyes","volume":"6","author":"Zhang","year":"2022","journal-title":"Ophthalmol Retin"},{"issue":"4","key":"10.1016\/j.survophthal.2024.02.005_bib125","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for Zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2024.02.005_bib126","unstructured":"Zhuang H., Lin L., Luo D., Zheng N.X. A Network Meta-Analysis of Success Rates following Low Dosage Anti-VEGF for Retinopathy of Prematurity. Curr Eye Res. 1\u20139."}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625724000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625724000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T03:37:53Z","timestamp":1710214673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625724000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":126,"alternative-id":["S0039625724000080"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2024.02.005","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2024.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}